Clinical Trial Update: The ctDNA-RECIST Trial Part One [Phase 2]

View source ↗

Summary

This update outlines a Phase 2 ctDNA-RECIST trial (Part One) that is currently recruiting for gastrointestinal neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neoplasm

Snippet

Sponsor: Karen-Lise Garm Spindler | Conditions: Gastrointestinal Neoplasm | Phase 2 | Status: RECRUITING